Is Madrigal Pharmaceuticals (MDGL) Cheap Following Rezdiffra Data And A Swing To Net Income?

Madrigal Pharmaceuticals (MDGL) is back in focus after releasing real world data on its MASH drug Rezdiffra at The Liver Meeting in Denver and reporting a swing to third quarter net income.

The recent swing to profitability and new real world evidence on Rezdiffra have shifted attention back to Madrigal Pharmaceuticals, yet the share price tells a more mixed story with a 1 day share price return of 8.3% and a year to date share price return that is down 27.1%. Over a longer stretch, total shareholder return is down 12.7% over the past year. However, investors who have held on for several years still sit on a gain of almost 4x over five years, which suggests momentum has cooled in the short run while confidence in the MASH opportunity is still influencing the long term record.

Spot check Madrigal Pharmaceuticals against a hand-picked group of late stage biotech and strong balance sheet plays using the list of solid balance sheet and fundamentals (25 results).

After a sharp single-day bounce but a weaker year-to-date record, Madrigal Pharmaceuticals now sits at a market value of about US$9.3b. Does that mix of new data, fresh profitability and past gains still skew the risk reward toward buyers?

Most Popular Narrative: 36.9% Undervalued

Madrigal Pharmaceuticals closed at $432.79, while the analyst consensus Narrative on Simply Wall St pins fair value at $686.06 using a 7.58% discount rate and detailed Rezdiffra forecasts, implying a sizeable valuation gap in favor of the bulls.

The rapid uptake and long term patent protection of Rezdiffra, now supported by additional Orange Book listed patents and guidance that coverage is expected into 2045, reinforces the potential for Madrigal Pharmaceuticals to maintain protected revenue and support gross margin strength for an extended period.

The growing diagnosed U.S. F2–F3 MASH population, which Madrigal Pharmaceuticals estimates at over 530,000 patients with around 10% diagnosis and roughly 10% Rezdiffra penetration, points to a large pool of untreated patients that can support future revenue expansion as awareness and treatment adoption increase.

See why 14 investors see Madrigal Pharmaceuticals as 37% undervalued.

Result: Fair Value of $686.06 (UNDERVALUED)

Still, the Madrigal Pharmaceuticals narrative leans heavily on a single drug, and higher SG&A plus rising gross-to-net pressure could undermine the current valuation case.

Find out about the key risks to this Madrigal Pharmaceuticals narrative.

Next Steps

Mixed signals or early inflection: either way, Madrigal Pharmaceuticals now splits opinion with clear risks and clear potential benefits on the table, so move fast and weigh both sides through the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Madrigal Pharmaceuticals?

If Madrigal Pharmaceuticals has your attention, do not stop here. Broaden your watchlist with fresh opportunities that match your risk tolerance and income goals.

• Search for potential mispricings by running your filters against a curated set of companies flagged as underappreciated value plays using the 33 high quality undervalued stocks.
• Consider companies with sturdier balance sheets and cleaner fundamentals by scanning the 30 resilient stocks with low risk scores.
• Explore candidates with stronger yields through the 6 dividend fortresses.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com